— Know what they know.
Not Investment Advice

ATAI NASDAQ

Atai Beckley Inc.
1W: +0.1% 1M: +1.7% 3M: +93.4% YTD: +89.9% 1Y: +55.7% 3Y: +410.4% 5Y: -57.4%
$7.35
Last traded 2026-09-11 — delisted
NASDAQ · Healthcare · Biotechnology · $2.7B mcap · 201M float · 5.70% daily turnover · Short 30% of daily vol

Supply Chain Overview

12 relationships
12
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-11-10
Earliest Filing
2025-11-05
Latest Filing
target: 5 investor: 4 partner: 3

Counterparties (Filed by ATAI)

12 relationships

Companies named in ATAI's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
Beckley Psytech Limited — target Target company acquired by Atai Beckley N.V. in a share-for-share transaction. 2025-11-05 View
Beckley Psytech Limited — target Target company in the Share Purchase Agreement acquisition 2025-10-27 View
Apeiron Investment Group Ltd. — investor Family office of Christian Angermayer participating in the PIPE Financing. 2025-07-01 View
Leerink Partners LLC — partner Joint-lead placement agent for the PIPE Financing. 2025-07-01 View
Berenberg Capital Markets LLC — partner Joint-lead placement agent for the PIPE Financing. 2025-07-01 View
Beckley Psytech Limited — target Target of acquisition; atai agreed to acquire its entire issued share capital not already owned. 2025-07-01 View
Ferring Ventures S.A. — investor Investor party to a Subscription Agreement for the PIPE Financing. 2025-07-01 View
Beckley Psytech Limited — investor Company in which the registrant holds a 35.5% strategic investment 2025-02-13 View
Recognify Life Sciences, Inc. — investor Company in which the registrant holds a 51.9% strategic investment 2025-02-13 View
Beckley Psytech Limited — target Acquisition of Series C preferred shares and additional shares for a total investment of approximately $50 million. 2024-01-23 View
Beckley Psytech Limited — target Acquisition of Series C preferred shares and secondary sale of BPL shares by ATAI Life Sciences N.V. 2024-01-04 View
Jefferies LLC JEF partner Acted as sales agent for the Company's at-the-market equity offering program. 2022-11-10 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-09-11 Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Director Change; Bylaws Amendm Acquisition View
2026-09-08 Shareholder Vote View
2026-08-31 Other Events View
2026-07-16 Material Agreement; Regulation FD; Exhibits Agreement View
2026-06-08 Shareholder Vote View
2026-06-03 Regulation FD View
2026-05-12 Earnings Release; Exhibits View
2025-12-05 Other Events; Financial Statements and Exhibits View
2025-11-12 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-11-05 Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Regulat Acquisition View
2025-11-05 Other Events; Financial Statements and Exhibits View
2025-11-04 Submission of Matters to a Vote of Security Holders View
2025-10-27 Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits Agreement View
2025-10-21 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2025-10-20 Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Regulation Agreement View
2025-10-16 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2025-10-10 Other Events; Financial Statements and Exhibits View
2025-09-29 Other Events; Financial Statements and Exhibits View
2025-09-23 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2025-08-14 Results of Operations and Financial Condition; Financial Statements and Exhibits View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms